Abbott Laboratories (NYSE: ABT) Stock Competitors & Peer Comparison
See ABT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABT | $109.96 | -0.50% | 191.1B | 21.20 | $5.21 | +2.29% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $101.46 | -1.29% | 130B | 18.38 | $5.53 | +2.82% |
| SYK | $317.95 | -2.39% | 123.4B | 24.21 | $13.39 | +1.09% |
| BSX | $45.39 | +3.11% | 64.8B | 14.42 | $3.10 | N/A |
| EW | $105.80 | +1.04% | 60B | 38.53 | $2.70 | N/A |
| GEHC | $82.72 | -1.56% | 37.8B | 17.07 | $4.90 | +0.17% |
| DXCM | $80.18 | -1.10% | 29.8B | 31.34 | $2.55 | N/A |
| PHG | $30.22 | -1.87% | 29.7B | 17.37 | $1.75 | +3.26% |
| ZBH | $106.76 | -1.45% | 20.5B | 12.66 | $8.48 | +0.89% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
ABT vs BSX-PA Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.09%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
ABT vs MDT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, MDT has a market cap of 130B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while MDT trades at $101.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas MDT's P/E ratio is 18.38. In terms of profitability, ABT's ROE is +0.09%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
ABT vs SYK Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SYK has a market cap of 123.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SYK trades at $317.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SYK's P/E ratio is 24.21. In terms of profitability, ABT's ROE is +0.09%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ABT is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
ABT vs BSX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BSX has a market cap of 64.8B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BSX trades at $45.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BSX's P/E ratio is 14.42. In terms of profitability, ABT's ROE is +0.09%, compared to BSX's ROE of +0.14%. Regarding short-term risk, ABT is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ABT vs EW Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, EW has a market cap of 60B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while EW trades at $105.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas EW's P/E ratio is 38.53. In terms of profitability, ABT's ROE is +0.09%, compared to EW's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for ABT.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ABT vs GEHC Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, GEHC has a market cap of 37.8B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while GEHC trades at $82.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas GEHC's P/E ratio is 17.07. In terms of profitability, ABT's ROE is +0.09%, compared to GEHC's ROE of +0.20%. Regarding short-term risk, ABT is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
ABT vs DXCM Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, DXCM has a market cap of 29.8B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while DXCM trades at $80.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas DXCM's P/E ratio is 31.34. In terms of profitability, ABT's ROE is +0.09%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ABT vs PHG Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PHG has a market cap of 29.7B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PHG trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PHG's P/E ratio is 17.37. In terms of profitability, ABT's ROE is +0.09%, compared to PHG's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ABT vs ZBH Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ZBH has a market cap of 20.5B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ZBH trades at $106.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ZBH's P/E ratio is 12.66. In terms of profitability, ABT's ROE is +0.09%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ABT is similarly volatile compared to ZBH. This indicates similar risk in terms of short-term price fluctuations for ABT.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ABT vs ABMD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.09%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
ABT vs GKOS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, GKOS has a market cap of 14B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while GKOS trades at $244.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas GKOS's P/E ratio is -274.57. In terms of profitability, ABT's ROE is +0.09%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
ABT vs SNN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SNN has a market cap of 13.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SNN trades at $31.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SNN's P/E ratio is 20.88. In terms of profitability, ABT's ROE is +0.09%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
ABT vs PEN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PEN trades at $321.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PEN's P/E ratio is 83.95. In terms of profitability, ABT's ROE is +0.09%, compared to PEN's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ABT vs SWAV Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.09%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ABT vs ALGN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ALGN trades at $171.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ALGN's P/E ratio is 15.89. In terms of profitability, ABT's ROE is +0.09%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ABT vs BIO-B Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BIO-B trades at $389.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BIO-B's P/E ratio is -68.67. In terms of profitability, ABT's ROE is +0.09%, compared to BIO-B's ROE of +0.14%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ABT.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ABT vs BIO Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BIO trades at $387.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BIO's P/E ratio is 41.73. In terms of profitability, ABT's ROE is +0.09%, compared to BIO's ROE of +0.14%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
ABT vs PODD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PODD trades at $149.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PODD's P/E ratio is 25.22. In terms of profitability, ABT's ROE is +0.09%, compared to PODD's ROE of +0.29%. Regarding short-term risk, ABT is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
ABT vs GMED Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while GMED trades at $74.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas GMED's P/E ratio is 16.94. In terms of profitability, ABT's ROE is +0.09%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKRP)
ABT vs BRKRP Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BRKRP trades at $455.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BRKRP's P/E ratio is 247.38. In terms of profitability, ABT's ROE is +0.09%, compared to BRKRP's ROE of -0.05%. Regarding short-term risk, ABT is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BRKRP's competition here
Bruker Corporation (NASDAQ: BRKR)
ABT vs BRKR Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BRKR has a market cap of 9.5B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BRKR trades at $62.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BRKR's P/E ratio is 31.28. In terms of profitability, ABT's ROE is +0.09%, compared to BRKR's ROE of -0.05%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
ABT vs MASI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas MASI's P/E ratio is 44.43. In terms of profitability, ABT's ROE is +0.09%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ABT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ABT.Check MASI's competition here
Haemonetics Corporation (NYSE: HAE)
ABT vs HAE Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, HAE has a market cap of 5.6B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while HAE trades at $120.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas HAE's P/E ratio is 24.44. In terms of profitability, ABT's ROE is +0.09%, compared to HAE's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ABT.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
ABT vs LIVN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, LIVN has a market cap of 5B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while LIVN trades at $91.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas LIVN's P/E ratio is 21.65. In terms of profitability, ABT's ROE is +0.09%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LIVN's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ABT vs NARI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.09%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ABT.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ABT vs ITGR Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ITGR trades at $126.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ITGR's P/E ratio is 19.94. In terms of profitability, ABT's ROE is +0.09%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, ABT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ITGR's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ABT vs TMDX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, TMDX has a market cap of 3.2B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while TMDX trades at $92.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas TMDX's P/E ratio is 46.16. In terms of profitability, ABT's ROE is +0.09%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ABT vs AXGN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, AXGN has a market cap of 3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while AXGN trades at $54.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas AXGN's P/E ratio is 133.92. In terms of profitability, ABT's ROE is +0.09%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AXGN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ABT vs IRTC Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, IRTC has a market cap of 2.8B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while IRTC trades at $87.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas IRTC's P/E ratio is -200.14. In terms of profitability, ABT's ROE is +0.09%, compared to IRTC's ROE of -0.23%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
ABT vs NEOG Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while NEOG trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas NEOG's P/E ratio is 41.75. In terms of profitability, ABT's ROE is +0.09%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ABT vs UFPT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while UFPT trades at $314.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas UFPT's P/E ratio is 32.08. In terms of profitability, ABT's ROE is +0.09%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ABT vs NUVA Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.09%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ABT vs ESTA Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ESTA trades at $70.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ESTA's P/E ratio is -53.36. In terms of profitability, ABT's ROE is +0.09%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ESTA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ABT vs INSP Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while INSP trades at $61.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas INSP's P/E ratio is 27.46. In terms of profitability, ABT's ROE is +0.09%, compared to INSP's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ABT vs BFLY Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BFLY trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BFLY's P/E ratio is -27.08. In terms of profitability, ABT's ROE is +0.09%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
ABT vs ENOV Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ENOV trades at $28.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ENOV's P/E ratio is 8.08. In terms of profitability, ABT's ROE is +0.09%, compared to ENOV's ROE of -0.36%. Regarding short-term risk, ABT is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ENOV's competition here
CONMED Corporation (NYSE: CNMD)
ABT vs CNMD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CNMD trades at $51.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CNMD's P/E ratio is 11.25. In terms of profitability, ABT's ROE is +0.09%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CNMD's competition here
Novocure Ltd (NASDAQ: NVCR)
ABT vs NVCR Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while NVCR trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas NVCR's P/E ratio is -11.14. In terms of profitability, ABT's ROE is +0.09%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, ABT is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NVCR's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ABT vs LMRI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, LMRI has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while LMRI trades at $15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas LMRI's P/E ratio is -27.08. In terms of profitability, ABT's ROE is +0.09%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ABT is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LMRI's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ABT vs PRCT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PRCT trades at $22.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PRCT's P/E ratio is -11.88. In terms of profitability, ABT's ROE is +0.09%, compared to PRCT's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PRCT's competition here
Heska Corporation (NASDAQ: HSKA)
ABT vs HSKA Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.09%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ABT.Check HSKA's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ABT vs TNDM Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while TNDM trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas TNDM's P/E ratio is -20.12. In terms of profitability, ABT's ROE is +0.09%, compared to TNDM's ROE of -0.36%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ABT vs AVNS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ABT's ROE is +0.09%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ABT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ABT.Check AVNS's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ABT vs IART Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while IART trades at $14.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas IART's P/E ratio is 6.16. In terms of profitability, ABT's ROE is +0.09%, compared to IART's ROE of +0.01%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IART's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ABT vs SIBN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SIBN trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SIBN's P/E ratio is -73.82. In terms of profitability, ABT's ROE is +0.09%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SIBN's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ABT vs SILK Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.09%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
ABT vs IRMD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while IRMD trades at $86.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas IRMD's P/E ratio is 43.58. In terms of profitability, ABT's ROE is +0.09%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ABT is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
ABT vs FNA Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.09%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ABT.Check FNA's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ABT vs ATEC Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ATEC has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ATEC trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ATEC's P/E ratio is -12.45. In terms of profitability, ABT's ROE is +0.09%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ATEC's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ABT vs CBLL Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CBLL has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CBLL trades at $27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CBLL's P/E ratio is -15.61. In terms of profitability, ABT's ROE is +0.09%, compared to CBLL's ROE of -0.55%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CBLL's competition here
Artivion, Inc. (NYSE: AORT)
ABT vs AORT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while AORT trades at $20.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas AORT's P/E ratio is 34.38. In terms of profitability, ABT's ROE is +0.09%, compared to AORT's ROE of -0.04%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AORT's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ABT vs AHCO Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, AHCO has a market cap of 1B. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while AHCO trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas AHCO's P/E ratio is 14.99. In terms of profitability, ABT's ROE is +0.09%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AHCO's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ABT vs KIDS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, KIDS has a market cap of 874.2M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while KIDS trades at $33.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas KIDS's P/E ratio is -24.99. In terms of profitability, ABT's ROE is +0.09%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check KIDS's competition here
Picard Medical, Inc. (AMEX: PMI)
ABT vs PMI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PMI has a market cap of 850.6M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PMI trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PMI's P/E ratio is -6.90. In terms of profitability, ABT's ROE is +0.09%, compared to PMI's ROE of -9.31%. Regarding short-term risk, ABT is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PMI's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ABT vs CSII Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.09%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ABT.Check CSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ABT vs VREX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, VREX has a market cap of 783.4M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while VREX trades at $18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas VREX's P/E ratio is 19.42. In terms of profitability, ABT's ROE is +0.09%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ABT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check VREX's competition here
Bioventus Inc. (NASDAQ: BVS)
ABT vs BVS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BVS has a market cap of 765.5M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BVS trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BVS's P/E ratio is 14.71. In terms of profitability, ABT's ROE is +0.09%, compared to BVS's ROE of +0.27%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
ABT vs INMD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, INMD has a market cap of 763.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while INMD trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas INMD's P/E ratio is 9.21. In terms of profitability, ABT's ROE is +0.09%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INMD's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ABT vs CTKB Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CTKB has a market cap of 757.2M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CTKB trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CTKB's P/E ratio is -30.67. In terms of profitability, ABT's ROE is +0.09%, compared to CTKB's ROE of -0.25%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CTKB's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ABT vs BBNX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BBNX has a market cap of 743.2M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BBNX trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BBNX's P/E ratio is -8.98. In terms of profitability, ABT's ROE is +0.09%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BBNX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ABT vs DCTH Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, DCTH has a market cap of 697.4M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while DCTH trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas DCTH's P/E ratio is 2010.00. In terms of profitability, ABT's ROE is +0.09%, compared to DCTH's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ABT.Check DCTH's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ABT vs PACB Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PACB has a market cap of 696.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PACB trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PACB's P/E ratio is -5.46. In terms of profitability, ABT's ROE is +0.09%, compared to PACB's ROE of +6.04%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ABT vs SRDX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ABT's ROE is +0.09%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ABT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SRDX's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ABT vs SGHT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SGHT has a market cap of 597.5M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SGHT trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SGHT's P/E ratio is -19.20. In terms of profitability, ABT's ROE is +0.09%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SGHT's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ABT vs TCMD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, TCMD has a market cap of 596.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while TCMD trades at $26.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas TCMD's P/E ratio is 24.65. In terms of profitability, ABT's ROE is +0.09%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TCMD's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ABT vs APEN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.09%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check APEN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ABT vs AVR Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, AVR has a market cap of 574M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while AVR trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas AVR's P/E ratio is -3.04. In terms of profitability, ABT's ROE is +0.09%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ABT vs ZIMV Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ABT's ROE is +0.09%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, ABT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ZIMV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ABT vs SENS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SENS has a market cap of 530.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SENS trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SENS's P/E ratio is -4.50. In terms of profitability, ABT's ROE is +0.09%, compared to SENS's ROE of -1.86%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SENS's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ABT vs RCEL Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, RCEL has a market cap of 438.5M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while RCEL trades at $17.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas RCEL's P/E ratio is -12.26. In terms of profitability, ABT's ROE is +0.09%, compared to RCEL's ROE of +1.46%. Regarding short-term risk, ABT is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RCEL's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ABT vs NPCE Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, NPCE has a market cap of 435.6M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while NPCE trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas NPCE's P/E ratio is -22.26. In terms of profitability, ABT's ROE is +0.09%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NPCE's competition here
Cerus Corporation (NASDAQ: CERS)
ABT vs CERS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CERS has a market cap of 393.8M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CERS trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CERS's P/E ratio is -64.78. In terms of profitability, ABT's ROE is +0.09%, compared to CERS's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CERS's competition here
CapsoVision, Inc. (NASDAQ: CV)
ABT vs CV Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CV has a market cap of 338.9M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CV trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CV's P/E ratio is -10.11. In terms of profitability, ABT's ROE is +0.09%, compared to CV's ROE of -1.78%. Regarding short-term risk, ABT is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CV's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ABT vs SSII Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SSII has a market cap of 322.8M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SSII trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SSII's P/E ratio is -26.83. In terms of profitability, ABT's ROE is +0.09%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SSII's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ABT vs TMCI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, TMCI has a market cap of 317.4M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while TMCI trades at $5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas TMCI's P/E ratio is -5.19. In terms of profitability, ABT's ROE is +0.09%, compared to TMCI's ROE of -0.76%. Regarding short-term risk, ABT is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ABT vs SMLR Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ABT's ROE is +0.09%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, ABT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SMLR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ABT vs INFU Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, INFU has a market cap of 304.1M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while INFU trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas INFU's P/E ratio is 37.24. In terms of profitability, ABT's ROE is +0.09%, compared to INFU's ROE of +0.16%. Regarding short-term risk, ABT is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INFU's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ABT vs OFIX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, OFIX has a market cap of 290M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while OFIX trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas OFIX's P/E ratio is -4.64. In terms of profitability, ABT's ROE is +0.09%, compared to OFIX's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check OFIX's competition here
Profound Medical Corp. (NASDAQ: PROF)
ABT vs PROF Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, PROF has a market cap of 281.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while PROF trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas PROF's P/E ratio is -7.84. In terms of profitability, ABT's ROE is +0.09%, compared to PROF's ROE of -0.31%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PROF's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ABT vs CLPT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CLPT has a market cap of 281.1M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CLPT trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CLPT's P/E ratio is -7.43. In terms of profitability, ABT's ROE is +0.09%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CLPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ABT vs QSI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, QSI has a market cap of 254.7M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while QSI trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas QSI's P/E ratio is -2.78. In terms of profitability, ABT's ROE is +0.09%, compared to QSI's ROE of -0.45%. Regarding short-term risk, ABT is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check QSI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ABT vs MGRM Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ABT's ROE is +0.09%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, ABT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ABT.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
ABT vs ELMD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ELMD has a market cap of 226.6M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ELMD trades at $25.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ELMD's P/E ratio is 20.87. In terms of profitability, ABT's ROE is +0.09%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
ABT vs NVRO Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.09%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ABT.Check NVRO's competition here
RxSight, Inc. (NASDAQ: RXST)
ABT vs RXST Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, RXST has a market cap of 205.5M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while RXST trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas RXST's P/E ratio is -4.34. In terms of profitability, ABT's ROE is +0.09%, compared to RXST's ROE of -0.20%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ABT vs BSGM Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ABT's ROE is +0.09%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ABT vs MDGS Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ABT's ROE is +0.09%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check MDGS's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ABT vs TLSI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, TLSI has a market cap of 175.5M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while TLSI trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas TLSI's P/E ratio is -1.70. In terms of profitability, ABT's ROE is +0.09%, compared to TLSI's ROE of +7.60%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TLSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ABT vs QIPT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ABT's ROE is +0.09%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, ABT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ABT.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
ABT vs INGN Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, INGN has a market cap of 159.2M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while INGN trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas INGN's P/E ratio is -6.59. In terms of profitability, ABT's ROE is +0.09%, compared to INGN's ROE of -0.20%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
ABT vs QTRX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, QTRX has a market cap of 155.1M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while QTRX trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas QTRX's P/E ratio is -1.29. In terms of profitability, ABT's ROE is +0.09%, compared to QTRX's ROE of -0.43%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check QTRX's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ABT vs STIM Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, STIM has a market cap of 153.2M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while STIM trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas STIM's P/E ratio is -4.57. In terms of profitability, ABT's ROE is +0.09%, compared to STIM's ROE of -1.28%. Regarding short-term risk, ABT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ABT vs FOCL Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, FOCL has a market cap of 131.2M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while FOCL trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas FOCL's P/E ratio is -3.38. In terms of profitability, ABT's ROE is +0.09%, compared to FOCL's ROE of -2.41%. Regarding short-term risk, ABT is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check FOCL's competition here
Owlet, Inc. (NYSE: OWLT)
ABT vs OWLT Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, OWLT has a market cap of 127.1M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while OWLT trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas OWLT's P/E ratio is -31.07. In terms of profitability, ABT's ROE is +0.09%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, ABT is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check OWLT's competition here
Pulmonx Corporation (NASDAQ: LUNG)
ABT vs LUNG Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, LUNG has a market cap of 121.9M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while LUNG trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas LUNG's P/E ratio is -2.77. In terms of profitability, ABT's ROE is +0.09%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, ABT is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LUNG's competition here
iCAD, Inc. (NASDAQ: ICAD)
ABT vs ICAD Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ABT's ROE is +0.09%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ABT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ABT vs HJLI Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas HJLI's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.09%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, ABT is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
ABT vs ASXC Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ABT's ROE is +0.09%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ABT is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ASXC's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ABT vs CATX Comparison November 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 191.1B. In comparison, CATX has a market cap of 90M. Regarding current trading prices, ABT is priced at $109.96 on the NYSE, while CATX trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.20, whereas CATX's P/E ratio is -0.59. In terms of profitability, ABT's ROE is +0.09%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CATX's competition here